Coherus Oncology (CHRS) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $9.0 million.
- Coherus Oncology's Income towards Parent Company fell 7561.33% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 21772.8%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
- Per Coherus Oncology's latest filing, its Income towards Parent Company stood at $9.0 million for Q3 2025, which was down 7561.33% from $342.6 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Income towards Parent Company peaked at $342.6 million during Q2 2025, and registered a low of -$172.9 million during Q1 2021.
- In the last 5 years, Coherus Oncology's Income towards Parent Company had a median value of -$39.6 million in 2023 and averaged -$1.4 million.
- In the last 5 years, Coherus Oncology's Income towards Parent Company tumbled by 58618.86% in 2021 and then soared by 71714.52% in 2025.
- Quarter analysis of 5 years shows Coherus Oncology's Income towards Parent Company stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then tumbled by 95.46% to $9.0 million in 2025.
- Its Income towards Parent Company was $9.0 million in Q3 2025, compared to $342.6 million in Q2 2025 and -$9.2 million in Q1 2025.